Psychiatric NP Scope of Practice for Anxiety in Michigan

If you’re a psychiatrist or PMHNP treating anxiety disorders via telehealth, you’re navigating one of the most complex regulatory landscapes in healthcare right now. The rules for prescribing anxiety medications remotely sit at the intersection of federal DEA policy, state medical boards, controlled substance laws, and telehealth statutes — and they’re still evolving.

Here’s what you actually need to know to practice legally and confidently in 2025-2026, whether you’re treating patients in California, Texas, Florida, New York, Pennsylvania, Illinois, or planning to expand across state lines.

Why This Matters More for Anxiety Providers

Unlike treating depression (where first-line meds are non-controlled SSRIs), anxiety treatment often involves controlled substances. Benzodiazepines like alprazolam, clonazepam, and lorazepam are Schedule IV controlled drugs — meaning they fall under the federal Ryan Haight Act, which was specifically designed to regulate ‘prescribing by means of the Internet.’

Before COVID-19, that law essentially required an in-person exam before you could prescribe any controlled substance via telehealth. The pandemic changed everything temporarily. As of February 2026, you can still prescribe benzodiazepines after a telehealth-only evaluation — but this flexibility is temporary and may end in 2026 or beyond.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Current Federal DEA Rules (Extended Through December 31, 2025)

The DEA and HHS announced their third extension of COVID-era telehealth prescribing rules through the end of 2025. This means:

What you CAN do right now:

• Prescribe Schedule II-V controlled substances (including benzodiazepines) via telehealth to new patients
• Conduct the initial evaluation entirely by video without any in-person visit
• Continue controlled substance prescriptions via telehealth for existing patients
• Practice this way in any state where you hold a valid license and DEA registration

What you MUST do:

• Conduct evaluations via real-time audiovisual telemedicine (video strongly recommended over audio-only for new patients)
• Follow all standard prescribing practices — legitimate medical purpose, proper documentation, clinical justification
• Comply with state PDMP requirements (checking prescription monitoring databases)
• Maintain DEA registration in your state of practice

What’s uncertain:The DEA proposed new rules in 2023 that would have reinstated in-person visit requirements, triggering 38,000+ public comments (mostly negative). They’ve postponed those rules while developing a ‘new path forward for telemedicine.’ Nobody knows exactly what the post-2025 landscape will look like.

Smart move: Don’t build your entire practice around telehealth-only controlled prescribing. Have a plan for hybrid care or be prepared to adjust if regulations tighten in 2026.

State-by-State Breakdown: Where the Rules Actually Differ

Federal DEA rules set the floor. States add layers on top. Here’s what matters in the six largest telehealth markets:

California: Telehealth-Friendly, But License-Intensive

The good news:

• No state-level requirement for in-person exams before prescribing via telehealth
• Telehealth evaluation (even asynchronous components) can satisfy the ‘appropriate prior examination’ requirement for prescribing
• No state ban on controlled substance prescribing via telehealth beyond federal rules

The regulatory reality:

• You must hold a full California medical license — no telehealth shortcuts, and CA isn’t in the Interstate Medical Licensure Compact (IMLC)
• Mandatory e-prescribing for all medications (since 2022)
• CURES PDMP check required within 24 hours of initially prescribing any Schedule II-IV drug, then at least every 4 months for ongoing therapy

For PMHNPs in California:

• Experienced NPs gained limited independence in 2023 (practice in certain settings without physician oversight)
• Full independence available starting January 2026 under AB 890 (if you meet the 3+ years experience requirement)
• Until then, you’ll need standardized procedures with a physician to prescribe

Bottom line: California is clinically permissive but administratively demanding. The license requirement means you can’t easily practice there from another state, but once licensed, you have broad telehealth prescribing authority.

Texas: Video Required, Schedule II Limits for NPs

The good news:

• Clear telemedicine framework (SB 1107, 2017) — no in-person visit required before prescribing
• Psychiatrists have full prescribing authority via telehealth for anxiety medications
• Texas joined IMLC in 2021, making it easier for out-of-state psychiatrists to get licensed

The rules that bite:

• Must establish care via synchronous audiovisual exam for new patients (video, not just phone)
• Chronic pain management via telehealth with controlled substances is heavily restricted — but this doesn’t affect psychiatric anxiety treatment
• Mandatory PDMP check before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol

For PMHNPs in Texas:

• You CANNOT prescribe Schedule II controlled substances in outpatient settings except in hospital/emergency/hospice contexts
• You must practice under a Prescriptive Authority Agreement (PAA) with a physician
• For anxiety treatment, this mainly matters if you’re managing comorbid ADHD (stimulants are Schedule II) — you’d need the collaborating physician to prescribe those

Bottom line: Texas is telehealth-permissive for psychiatrists, restrictive for NPs. The video requirement is non-negotiable. If you’re joining a platform like Klarity, they’ll handle the physician collaboration infrastructure for NP practice.

Florida: Psychiatric Exception Saves the Day

The unique rule:Florida law prohibits prescribing Schedule II controlled substances via telehealth — except for four situations, and one of them is treatment of psychiatric disorders. This was designed specifically to preserve access to mental health care.

What this means:

• Psychiatrists and psychiatric NPs can prescribe stimulants (for ADHD/anxiety) via telehealth under the psychiatric exception
• For typical anxiety treatment (benzodiazepines, which are Schedule IV), there’s no restriction
• You must obtain documented patient consent for telehealth treatment

Florida’s licensing flexibility:

• Out-of-state providers can obtain a Telehealth Provider Registration to practice in Florida without a full FL license (unique among major states)
• You’ll need fingerprinting and malpractice insurance, but it’s faster than full licensure
• Florida is in IMLC for physicians who want the full license route

For PMHNPs in Florida:

• You must practice under a physician supervisory protocol (psychiatric NPs are excluded from Florida’s independent practice law)
• You can prescribe Schedule II for psychiatric conditions, but only if you’re a certified ‘psychiatric nurse’ — and even then, max 7-day supply unless treating mental illness (then the limit doesn’t apply)
• One physician can supervise up to 4 NPs

PDMP requirement:

• E-FORCSE check required before any Schedule II-V prescription and every 90 days for ongoing therapy
• E-prescribing mandatory for all controlled substances

Bottom line: Florida built in psychiatric exceptions recognizing the realities of mental health prescribing. The telehealth registration option is a major advantage for expanding practice.

New York: Independent NPs, Mandatory PDMP Checks

The progressive shift:

• Experienced NPs (3,600+ hours) can practice independently without physician collaboration (made permanent in 2022)
• This means a seasoned PMHNP can run an independent telehealth anxiety practice in NY

The compliance burden:

• I-STOP law requires PDMP consultation before every Schedule II, III, or IV prescription — this includes every benzodiazepine refill
• Mandatory e-prescribing for all medications (since 2016)
• No telehealth license available; you must hold a full NY medical license (NY isn’t in IMLC)

What works:

• No state-imposed in-person exam requirement for telehealth prescribing
• Audio-only telehealth explicitly permitted for mental health services (though video is better practice for evaluations)
• Strong insurance parity laws mean Medicaid and private payers cover telepsychiatry

Bottom line: New York trusts experienced providers but watches them closely through PDMP requirements. For new NPs, you’ll need a collaborative agreement until you hit the 3,600-hour threshold. For psychiatrists, it’s straightforward once you’re licensed.

Pennsylvania: Benzodiazepine-Specific PDMP Rules

The regulatory landscape:

• No comprehensive telehealth statute until recently, but medical boards permit telemedicine if standard of care is met
• Real-time interactive audiovisual recommended for initial exams
• PA joined IMLC in 2017 (easier licensing for physicians)

The prescribing rules that matter:

• PDMP check required before initial prescription of any opioid or benzodiazepine
• More importantly: PDMP check required each time you prescribe or refill these medications (not just initially)
• E-prescribing mandatory for controlled substances (Act 96, 2019)

For PMHNPs in Pennsylvania:

• Must practice under a collaborative agreement with a physician
• Can prescribe Schedule II controlled substances for up to 30-day supply
• Can prescribe Schedule III-IV (including benzos) for up to 90-day supply
• Collaborating physician must be notified of Schedule II prescriptions within 24 hours

Bottom line: Pennsylvania’s PDMP requirements are more stringent than most states for benzodiazepines specifically. If you’re managing ongoing benzo prescriptions, factor in the time for database checks at every visit. NP autonomy bills have been introduced but haven’t passed as of early 2026.

Illinois: Full Practice Authority Available for NPs

The opportunity:

• Illinois allows NPs with 4,000+ hours of experience and additional training to obtain Full Practice Authority (FPA) — independent practice including prescribing
• Mental health services explicitly permitted via audio-only telehealth if necessary
• IL joined IMLC (2018) for physicians and Nurse Licensure Compact (2022) for RNs

The nuances:

• NPs with FPA prescribing Schedule II narcotics (opioids) must maintain a physician consultation relationship for first 5 years — but this doesn’t apply to non-narcotic Schedule II or to benzodiazepines (Schedule IV)
• Without FPA, you need a collaborative agreement; physician can collaborate with up to 5 APRNs
• Separate Illinois controlled substance license required (in addition to DEA registration)

PDMP requirements:

• Must register and consult Illinois PMP for all Schedule II prescriptions
• Law strongly encourages (effectively requires) PMP check for benzodiazepines

Bottom line: Illinois offers a genuine path to NP independence, which is rare in large states. For psychiatrists, it’s straightforward. The audio-only telehealth provision recognizes that some anxious patients struggle with video.

The Practical Realities: Economics and Patient Acquisition

Let’s talk about what nobody mentions in regulatory guides: the business side of telehealth anxiety treatment.

Why Platform Economics Make Sense

You could try building your own telehealth practice. Here’s what that actually costs:

DIY marketing reality check:

• Google Ads for mental health keywords: $15-40+ per click
• Realistic cost per booked patient through PPC: $200-400+ (factoring in clicks that don’t convert, no-shows from cold leads, ongoing optimization)
• SEO investment: 6-12 months of consistent spending before meaningful patient flow, typically $2,000-5,000/month for content, technical SEO, and link building
• Directory listings (Psychology Today, Zocdoc): monthly fees PLUS you’re competing with hundreds of providers on the same page
• Zocdoc’s per-booking fees: $35-100+ per new patient, plus monthly subscription
• Agency or consultant fees if you don’t do this yourself: add another $2,000-3,000/month

Total realistic monthly marketing spend for a solo provider: $3,000-5,000+ with uncertain ROI, especially in the first 6-12 months.

The Klarity Health Model

Instead of gambling $50,000+ on marketing in your first year with no guaranteed results, Klarity uses a pay-per-appointment model:

• No upfront marketing spend
• No monthly subscription fees
• Standard listing fee per new patient lead
• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs to worry about)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

The economics: Instead of spending thousands per month hoping to acquire patients, you pay a known amount per booked appointment. That’s guaranteed ROI versus gambling on marketing channels you may not have the expertise to optimize.

Can DIY marketing eventually be cost-effective? Sure — if you have the budget to sustain 6-12 months of investment before seeing returns, the expertise to run campaigns effectively (or money to hire experts), and the patience to test and optimize while your calendar sits empty.

For most providers, especially those starting out, scaling up, or working part-time in telehealth, a platform that handles patient acquisition removes the financial risk entirely.

Compliance Checklist: What You Actually Need

For All Providers (Psychiatrists and PMHNPs):

Licensing:

• [ ] Valid medical license or APRN license in every state where your patients are located
• [ ] DEA registration in your primary practice state
• [ ] State controlled substance license if required (IL, FL require separate state CS license)
• [ ] IMLC licensure or individual state licenses for multi-state practice

Technology:

• [ ] HIPAA-compliant video platform
• [ ] E-prescribing system with DEA-compliant two-factor authentication for controlled substances
• [ ] EHR or documentation system that meets state standards

Before Every Controlled Prescription:

• [ ] Check state PDMP (requirements vary: NY checks every time, CA every 4 months, PA every time for benzos, etc.)
• [ ] Document clinical justification in patient chart
• [ ] Verify patient identity and location (important for state licensing compliance)
• [ ] Obtain and document patient consent for telehealth treatment (required in FL, IL, best practice everywhere)

Practice Standards:

• [ ] Conduct evaluations via real-time video when possible (required in TX, strongly recommended everywhere)
• [ ] Document that encounter was via telehealth and note modality used
• [ ] Have emergency protocols in place (local crisis resources for patient’s location)
• [ ] Maintain same standard of care as in-person visits

Additional for PMHNPs (State-Dependent):

In restricted practice states (TX, FL, PA):

• [ ] Current collaborative agreement or supervisory protocol with physician on file
• [ ] Verify collaborating physician is licensed in the state and available for consultation
• [ ] Ensure your scope of practice agreement explicitly covers controlled substance prescribing
• [ ] Know your state’s specific limits (e.g., TX no Schedule II outpatient, PA 30-day max for Schedule II)

In full practice states (NY after 3,600 hrs, IL with FPA, CA by 2026):

• [ ] Documentation proving you meet the experience/training requirements for independence
• [ ] If IL with FPA prescribing Schedule II opioids: physician consultation relationship documented

What’s Coming: Preparing for Regulatory Changes

The DEA is working on ‘a new path forward’ for telemedicine prescribing, expected sometime in 2026. Possible scenarios:

Scenario 1: Hybrid requirement — Telehealth allowed for initial prescription, but in-person visit required within 30-90 days to continue controlled substance therapy.

Scenario 2: Special telemedicine registration — DEA finally implements the ‘special registration’ provision in the Ryan Haight Act, allowing providers to prescribe controlled substances via telehealth if they obtain this additional DEA credential.

Scenario 3: Medication-specific rules — Different rules for different drug categories (e.g., buprenorphine for OUD remains telehealth-friendly, stimulants require in-person, benzodiazepines get hybrid treatment).

Scenario 4: Status quo extension — Pressure from the mental health community leads to another extension or permanent adoption of current flexibilities.

How to prepare:

• Build relationships with local clinics or practices where patients could get in-person visits if needed
• Don’t build a practice 100% dependent on telehealth-only controlled prescribing
• Consider hybrid models now (offering both telehealth and some in-person availability)
• Stay connected to professional organizations (APA, AANP) that will advocate during the rulemaking process

The Bottom Line for Providers

If you’re a psychiatrist, you have maximum flexibility — full prescribing authority in all states, no supervision requirements, and the ability to leverage IMLC for multi-state licensing. Your main compliance burden is navigating each state’s PDMP requirements and ensuring proper licensure.

If you’re a PMHNP, your practice reality depends heavily on where your patients are located. In states moving toward full practice authority (NY, IL, CA), you can build an independent telehealth anxiety practice. In restricted states (TX, FL, PA), you’ll need physician collaboration — which platforms like Klarity can facilitate, but solo practice is more complicated.

For both: The telehealth prescribing landscape for anxiety treatment is more permissive right now than it may be in two years. If you’ve been thinking about telehealth practice, 2025-2026 is the time to establish yourself before potential regulatory tightening.

Why Klarity Makes Sense Right Now

Regulations are complex and changing. Patient acquisition is expensive and uncertain. Insurance credentialing is time-consuming. Klarity handles all of this:

• Compliance infrastructure adapted to each state’s rules
• Pre-qualified patient flow so you’re not gambling on marketing
• Multi-state licensing support to help you expand your practice
• Built-in telehealth platform meeting all technical requirements
• Pay-per-appointment model eliminating financial risk

Instead of spending 6 months and $30,000+ figuring out telehealth marketing, state regulations, and platform setup, you could see your first patients next week.

[Join Klarity’s Provider Network →]

References and Sources

The following sources were used to ensure accuracy of regulatory information as of February 2026:

1. DEA & HHS Telemedicine Extension Announcement (November 15, 2024) – Official DEA press release extending COVID-era telehealth prescribing flexibilities through December 31, 2025. www.dea.gov

2. 21 U.S.C. § 829(e) – Ryan Haight Act (Current through 2025) – Federal controlled substance prescribing requirements and telemedicine exceptions. www.law.cornell.edu

3. Center for Connected Health Policy – Online Prescribing Laws (Updated January 9, 2026) – Comprehensive state-by-state telehealth prescribing regulations with official citations. www.cchpca.org

4. Florida Statutes § 456.47 & § 464.012 (2025 edition) – Florida telehealth services law and APRN controlled substance prescribing authority including psychiatric exceptions. www.flsenate.gov

5. New York State Department of Health – I-STOP/PDMP Program (Effective August 27, 2013, accessed 2025) – New York’s mandatory prescription monitoring program requirements for Schedule II-IV prescriptions. health.ny.gov

Source:

• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=forward%20for%20telemedicine%2C%20DEA%20and,through%20the%20end%20of%202024
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Controlled%20Substance%20Act
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Note%20that%20the%20practice%20of,chapter%205%20of%20title%205
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,services%20within%20the%20applicable%20scope
• https://healthweb-back.health.ny.gov/professionals/narcotic/prescription_monitoring/#:~:text=Effective%20August%2027%2C%202013%2C%20most,to%20view%20dispensed%20controlled%20substance
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=may%20prescribe%20Schedule%20II%20drugs%3F,care%20from%20a%20qualified%20hospice
• https://www.leg.state.fl.us/Statutes/index.cfm?Appmode=DisplayStatute&Search_String=&URL=0400-0499%2F0464%2FSections%2F0464.012.html#:~:text=893.03%20to%20a%207,formulary%20which%20it%20finds%20is
• https://www.flsenate.gov/Laws/Statutes/2025/456.47#:~:text=,is%20prescribed%20for%20the%20following
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Additionally%2C%20the%20rule%20shall%20state,addiction%20medicine%2C%20or%20palliative%20care
• https://www.cchpca.org/topic/online-prescribing/#:~:text=The%20Attorney%20General%20may%20issue,application%20for%20such%20special%20registration%E2%80%94